Developer docs
API playgroundTry for free, no card

Search company profiles

Eloxx

Full company profile

uuid0003ya9

Namestring
Eloxx
Legal namestring
Eloxx Pharmaceuticals, Inc.
Websiteurl
eloxxpharma.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies that restore full-length protein production in patients with rare genetic diseases caused by nonsense mutations. Its lead compound, exaluren, is a novel eukaryotic ribosome-selective glycoside designed to selectively modulate the human ribosome at premature stop codons, enabling near-cognate aminoacyl-tRNA insertion and continued translation in place of the truncated peptides produced by nonsense alleles. Exaluren is administered subcutaneously and concentrated in kidney cells via megalin receptor-mediated uptake, supporting a precision nephrology positioning across two indications: nonsense mutation Alport syndrome (NMAS), currently in the EXACT Phase 2b study (NCT07523581), and nonsense mutation autosomal dominant polycystic kidney disease (NM-ADPKD), in Phase 2 planning. A second asset, ZKN-013, has been exclusively licensed to Almirall, S.A. for rare dermatological diseases (RDEB and JEB) and is in Phase 1 development.

The company's underlying technology is a gene-agnostic readthrough platform: by targeting the ribosome rather than any single gene, the same mechanism can be applied across COL4A3, COL4A4, and COL4A5 (Alport), PKD1 and PKD2 (ADPKD), and COL7A1, LAMA3, and COL17A1 (dermatology). The selectivity profile for human versus mitochondrial and bacterial ribosomes is intended to avoid the ototoxicity and nephrotoxicity associated with aminoglycoside-class antibiotics, addressing the historical safety ceiling of nonsense suppression approaches. Recent proof-of-concept data showed 100% (3/3) biopsy-confirmed disease regression in NMAS patients treated with ELX-02, with new protein analyses confirming production of both collagen α3 and α4/α5 post-treatment.

Eloxx is pre-revenue with no commercialized products and no public pricing. The business model is a hybrid of clinical development for retained indications (exaluren for NMAS and NM-ADPKD) and out-licensed development for non-core assets (ZKN-013 to Almirall, with $3 million upfront and up to $470 million in potential milestones plus tiered royalties). The company is publicly traded on the Nasdaq Capital Market under ticker ELOX following a $66.0 million offering in June 2026 and is headquartered in Waltham, Massachusetts. Customer-facing activity today is concentrated in clinical trial recruitment through patient advocacy partnerships (Alport Syndrome Foundation, PKD Foundation), scientific/medical engagement at nephrology conferences (ASN Kidney Week), and investor communications rather than commercial promotion.

Short descriptiontext

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing exaluren, a small-molecule ribosome modulator that induces premature stop codon readthrough to restore full-length proteins in patients with nonsense mutation Alport syndrome and ADPKD. The company is pre-revenue and Nasdaq-listed.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare kidney disease therapeutics, nonsense mutation readthrough, premature termination codon therapy, ribosome-selective glycoside platform, clinical-stage biopharmaceutical
Industry1 code
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage biopharmaceuticals (rare disease therapeutics)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage company. Anticipated revenue from commercialization of investigational therapies (exaluren, ZKN-013) following regulatory approval. Future revenue model will likely follow specialty pharmaceutical distribution through pharmacy channels upon FDA approval.

eloxxpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Exaluren
Description

A small molecule therapy designed to induce premature termination codon readthrough to restore full-length proteins, being developed for nonsense mutation Alport syndrome and ADPKD.

eloxxpharma.com
Core offering1 text field

Eloxx is developing exaluren, a novel eukaryotic ribosome-selective glycoside designed to induce premature termination codon readthrough and restore full-length functional proteins in patients with rare genetic diseases caused by nonsense mutations. The lead program is in the EXACT Phase 2b trial for nonsense mutation Alport syndrome, with a Phase 2 study planned for nonsense mutation ADPKD. A second asset, ZKN-013, has been exclusively licensed to Almirall for rare skin diseases including RDEB and JEB.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 100% response rate (3/3 Alport patients treated with ELX-02 had biopsy-confirmed disease regression)
+2 more records
Product overview1 text field

Eloxx is a clinical-stage biopharmaceutical company developing a single core compound, Exaluren, across two genetically defined kidney indications: nonsense mutation Alport syndrome (NMAS) and nonsense mutation autosomal dominant polycystic kidney disease (NM-ADPKD). Exaluren is a novel eukaryotic ribosome-selective glycoside designed to induce premature termination codon readthrough, restoring full-length protein production. The company also has a second compound, ZKN-013, which has been exclusively licensed to Almirall, S.A. for rare dermatological diseases (RDEB and JEB). Both programs share the company's gene-agnostic nonsense mutation readthrough technology platform.

Product and service2 records
1Exaluren
CategoryInvestigational rare kidney disease therapy
Description

Exaluren is a novel eukaryotic ribosome-selective glycoside (ERSG) product candidate designed to induce premature termination codon readthrough at nonsense mutations and promote the restoration of full-length functional proteins. Administered subcutaneously, it is transported and concentrated into kidney cells via megalin receptor-mediated uptake. It is being developed for nonsense mutation Alport syndrome (COL4A3/COL4A4/COL4A5) and nonsense mutation ADPKD (PKD1/PKD2).

2ZKN-013
CategoryInvestigational rare dermatology therapy (licensed)
Description

ZKN-013 is a ribosome modulating agent exclusively licensed to Almirall, S.A. for the development and commercialization of treatments for rare skin diseases caused by nonsense mutations, including recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB), targeting COL7A1, LAMA3, and COL17A1 nonsense mutations. Almirall is responsible for all development and commercialization; Eloxx receives $3M upfront, up to $470M in milestones, and tiered royalties.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-03-13
Description

Eloxx has exclusively licensed ZKN-013 to Almirall, S.A. for the development and commercialization of treatments for rare skin diseases caused by nonsense mutations, including RDEB (Recessive Dystrophic Epidermolysis Bullosa) and JEB (Junctional Epidermolysis Bullosa). Eloxx receives $3 million upfront payment and is eligible for up to $470 million in development and commercial milestones plus tiered royalties on global sales. Almirall is responsible for all development and commercialization activities.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage rare disease company developing RNA-targeted and gene therapies for Duchenne muscular dystrophy and other genetic diseases. Highly comparable to Eloxx as a rare genetic disease biotech pursuing novel RNA/protein-restoration mechanisms with specialty distribution.

TypeDirect peer
Description

Rare disease biotech with an approved topical gene therapy for dystrophic epidermolysis bullosa (EB). Directly comparable to Eloxx's ZKN-013 program targeting RDEB/JEB nonsense mutations and represents the competitive benchmark in EB.

TypeDirect peer
Description

Clinical-to-commercial rare genetic disease company with programs in nephrology (e.g., atrasentan in IgA nephropathy) and other inherited conditions. Closely comparable as a rare-genetic-disease platform with kidney-focused assets.

TypeDirect peer
Description

Rare disease company with a commercial and late-stage pipeline in kidney diseases (FSGS, IgA nephropathy). Comparable to Eloxx's nephrology focus and rare-disease commercial pathway planning.

TypeDirect peer
Description

Clinical-stage rare disease biotech with programs in epidermolysis bullosa and other genetic conditions. Comparable as an EB-focused player competing with ZKN-013 (via Almirall) for the same RDEB/JEB patient populations.

TypeBroad incumbent
Description

Established rare-disease leader with the dominant cystic fibrosis franchise (Trikafta). Historically funded Eloxx-adjacent nonsense mutation CF research and represents the broad incumbent comparator for specialty rare-disease commercialization.

TypeBroad incumbent
Description

Broad RNA-targeted therapeutics platform with multiple approved rare-disease antisense drugs. Comparable to Eloxx as an RNA/protein-modulation platform addressing genetic diseases, though at much larger scale.

TypeBroad incumbent
Description

Rare kidney disease biotech (acquired by Novartis) developing therapies for IgA nephropathy and other kidney conditions. Comparable to Eloxx as a kidney-focused rare-disease developer, now operating as part of a large incumbent.

TypeEmerging player
Description

Clinical-stage rare genetic disease biotech developing therapies for hematologic disorders. Comparable as a similarly staged rare-genetic-disease company pursuing novel mechanism-based therapies for small patient populations.

TypeEmerging player
Description

Clinical-stage cell therapy company focused on kidney disease (diabetic kidney disease, CKD). Comparable as an emerging nephrology-focused biotech addressing rare/serious kidney indications through novel mechanisms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eloxx

Clinical-stage biopharmaceuticals (rare disease therapeutics)eloxxpharma.com

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing exaluren, a small-molecule ribosome modulator that induces premature stop codon readthrough to restore full-length proteins in patients with nonsense mutation Alport syndrome and ADPKD. The company is pre-revenue and Nasdaq-listed.

What Eloxx does

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies that restore full-length protein production in patients with rare genetic diseases caused by nonsense mutations. Its lead compound, exaluren, is a novel eukaryotic ribosome-selective glycoside designed to selectively modulate the human ribosome at premature stop codons, enabling near-cognate aminoacyl-tRNA insertion and continued translation in place of the truncated peptides produced by nonsense alleles. Exaluren is administered subcutaneously and concentrated in kidney cells via megalin receptor-mediated uptake, supporting a precision nephrology positioning across two indications: nonsense mutation Alport syndrome (NMAS), currently in the EXACT Phase 2b study (NCT07523581), and nonsense mutation autosomal dominant polycystic kidney disease (NM-ADPKD), in Phase 2 planning. A second asset, ZKN-013, has been exclusively licensed to Almirall, S.A. for rare dermatological diseases (RDEB and JEB) and is in Phase 1 development.

The company's underlying technology is a gene-agnostic readthrough platform: by targeting the ribosome rather than any single gene, the same mechanism can be applied across COL4A3, COL4A4, and COL4A5 (Alport), PKD1 and PKD2 (ADPKD), and COL7A1, LAMA3, and COL17A1 (dermatology). The selectivity profile for human versus mitochondrial and bacterial ribosomes is intended to avoid the ototoxicity and nephrotoxicity associated with aminoglycoside-class antibiotics, addressing the historical safety ceiling of nonsense suppression approaches. Recent proof-of-concept data showed 100% (3/3) biopsy-confirmed disease regression in NMAS patients treated with ELX-02, with new protein analyses confirming production of both collagen α3 and α4/α5 post-treatment.

Eloxx is pre-revenue with no commercialized products and no public pricing. The business model is a hybrid of clinical development for retained indications (exaluren for NMAS and NM-ADPKD) and out-licensed development for non-core assets (ZKN-013 to Almirall, with $3 million upfront and up to $470 million in potential milestones plus tiered royalties). The company is publicly traded on the Nasdaq Capital Market under ticker ELOX following a $66.0 million offering in June 2026 and is headquartered in Waltham, Massachusetts. Customer-facing activity today is concentrated in clinical trial recruitment through patient advocacy partnerships (Alport Syndrome Foundation, PKD Foundation), scientific/medical engagement at nephrology conferences (ASN Kidney Week), and investor communications rather than commercial promotion.

Eloxx firmographics

Firmographics
Name
Eloxx
Legal name
Eloxx Pharmaceuticals, Inc.
Website
https://eloxxpharma.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing exaluren, a small-molecule ribosome modulator that induces premature stop codon readthrough to restore full-length proteins in patients with nonsense mutation Alport syndrome and ADPKD. The company is pre-revenue and Nasdaq-listed.
Ownership category
akta.pro rank

Eloxx industry classification

Industry
Product category
Clinical-stage biopharmaceuticals (rare disease therapeutics)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare kidney disease therapeutics
  • Nonsense mutation readthrough
  • Premature termination codon therapy
  • Ribosome-selective glycoside platform
  • Clinical-stage biopharmaceutical

Where Eloxx is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Eloxx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Anticipated revenue from commercialization of investigational therapies (exaluren, ZKN-013) following regulatory approval. Future revenue model will likely follow specialty pharmaceutical distribution through pharmacy channels upon FDA approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Eloxx product offering

Product offering

Core offering

Eloxx is developing exaluren, a novel eukaryotic ribosome-selective glycoside designed to induce premature termination codon readthrough and restore full-length functional proteins in patients with rare genetic diseases caused by nonsense mutations. The lead program is in the EXACT Phase 2b trial for nonsense mutation Alport syndrome, with a Phase 2 study planned for nonsense mutation ADPKD. A second asset, ZKN-013, has been exclusively licensed to Almirall for rare skin diseases including RDEB and JEB.

Product overview

Eloxx is a clinical-stage biopharmaceutical company developing a single core compound, Exaluren, across two genetically defined kidney indications: nonsense mutation Alport syndrome (NMAS) and nonsense mutation autosomal dominant polycystic kidney disease (NM-ADPKD). Exaluren is a novel eukaryotic ribosome-selective glycoside designed to induce premature termination codon readthrough, restoring full-length protein production. The company also has a second compound, ZKN-013, which has been exclusively licensed to Almirall, S.A. for rare dermatological diseases (RDEB and JEB). Both programs share the company's gene-agnostic nonsense mutation readthrough technology platform.

Differentiator

Problem solved

Functional benefit

Brands

  • Exaluren: A small molecule therapy designed to induce premature termination codon readthrough to restore full-length proteins, being developed for nonsense mutation Alport syndrome and ADPKD.

Products and services

  • Exaluren Exaluren is a novel eukaryotic ribosome-selective glycoside (ERSG) product candidate designed to induce premature termination codon readthrough at nonsense mutations and promote the restoration of full-length functional proteins. Administered subcutaneously, it is transported and concentrated into kidney cells via megalin receptor-mediated uptake. It is being developed for nonsense mutation Alport syndrome (COL4A3/COL4A4/COL4A5) and nonsense mutation ADPKD (PKD1/PKD2).
  • ZKN-013 ZKN-013 is a ribosome modulating agent exclusively licensed to Almirall, S.A. for the development and commercialization of treatments for rare skin diseases caused by nonsense mutations, including recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB), targeting COL7A1, LAMA3, and COL17A1 nonsense mutations. Almirall is responsible for all development and commercialization; Eloxx receives $3M upfront, up to $470M in milestones, and tiered royalties.

Quantifiable outcome

  • 100% response rate (3/3 Alport patients treated with ELX-02 had biopsy-confirmed disease regression)
  • +2 more outcomes

Companies that use Eloxx

Customer profile

Segments3 records

Ideal customer profiles3 records

Eloxx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Eloxx partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Almirall, S.A.coreOEM/ Whitelabel/ Licensing Partner · 13 March 2024Eloxx has exclusively licensed ZKN-013 to Almirall, S.A. for the development and commercialization of treatments for rare skin diseases caused by nonsense mutations, including RDEB (Recessive Dystrophic Epidermolysis Bullosa) and JEB (Junctional Epidermolysis Bullosa). Eloxx receives $3 million upfront payment and is eligible for up to $470 million in development and commercial milestones plus tiered royalties on global sales. Almirall is responsible for all development and commercialization activities.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Eloxx competitors and assessment

Company assessment

Direct peers

  • Sarepta Therapeutics: Commercial-stage rare disease company developing RNA-targeted and gene therapies for Duchenne muscular dystrophy and other genetic diseases. Highly comparable to Eloxx as a rare genetic disease biotech pursuing novel RNA/protein-restoration mechanisms with specialty distribution.
  • Krystal Biotech: Rare disease biotech with an approved topical gene therapy for dystrophic epidermolysis bullosa (EB). Directly comparable to Eloxx's ZKN-013 program targeting RDEB/JEB nonsense mutations and represents the competitive benchmark in EB.
  • BridgeBio Pharma: Clinical-to-commercial rare genetic disease company with programs in nephrology (e.g., atrasentan in IgA nephropathy) and other inherited conditions. Closely comparable as a rare-genetic-disease platform with kidney-focused assets.
  • Travere Therapeutics: Rare disease company with a commercial and late-stage pipeline in kidney diseases (FSGS, IgA nephropathy). Comparable to Eloxx's nephrology focus and rare-disease commercial pathway planning.
  • Abeona Therapeutics: Clinical-stage rare disease biotech with programs in epidermolysis bullosa and other genetic conditions. Comparable as an EB-focused player competing with ZKN-013 (via Almirall) for the same RDEB/JEB patient populations.

Broad incumbents

  • Vertex Pharmaceuticals: Established rare-disease leader with the dominant cystic fibrosis franchise (Trikafta). Historically funded Eloxx-adjacent nonsense mutation CF research and represents the broad incumbent comparator for specialty rare-disease commercialization.
  • Ionis Pharmaceuticals: Broad RNA-targeted therapeutics platform with multiple approved rare-disease antisense drugs. Comparable to Eloxx as an RNA/protein-modulation platform addressing genetic diseases, though at much larger scale.
  • Chinook Therapeutics (Novartis): Rare kidney disease biotech (acquired by Novartis) developing therapies for IgA nephropathy and other kidney conditions. Comparable to Eloxx as a kidney-focused rare-disease developer, now operating as part of a large incumbent.

Emerging players

  • Disc Medicine: Clinical-stage rare genetic disease biotech developing therapies for hematologic disorders. Comparable as a similarly staged rare-genetic-disease company pursuing novel mechanism-based therapies for small patient populations.
  • ProKidney: Clinical-stage cell therapy company focused on kidney disease (diabetic kidney disease, CKD). Comparable as an emerging nephrology-focused biotech addressing rare/serious kidney indications through novel mechanisms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Eloxx social profiles

Digital presence

Eloxx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eloxx leadership team

Management profile

Number of profiles

Profiles5 records

Eloxx funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eloxx M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eloxx

What does Eloxx do?

Eloxx is developing exaluren, a novel eukaryotic ribosome-selective glycoside designed to induce premature termination codon readthrough and restore full-length functional proteins in patients with rare genetic diseases caused by nonsense mutations. The lead program is in the EXACT Phase 2b trial for nonsense mutation Alport syndrome, with a Phase 2 study planned for nonsense mutation ADPKD. A second asset, ZKN-013, has been exclusively licensed to Almirall for rare skin diseases including RDEB and JEB.

Is Eloxx a public or private company?

Eloxx is a public company. It is classified as public and is currently operating.

When was Eloxx founded?

Eloxx was founded in 2013. It employs 11 to 50 people.

Where is Eloxx based?

Eloxx is headquartered in Watertown, United States, in the North America region.

How does Eloxx make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Eloxx's main competitors?

Direct peers on record are Sarepta Therapeutics, Krystal Biotech, BridgeBio Pharma, Travere Therapeutics and Abeona Therapeutics. Broad incumbents are Vertex Pharmaceuticals, Ionis Pharmaceuticals and Chinook Therapeutics (Novartis). Emerging players are Disc Medicine and ProKidney.

Does Eloxx have an API?

No public API is recorded for Eloxx.

What industry is Eloxx in?

Eloxx's product category is Clinical-stage biopharmaceuticals (rare disease therapeutics). Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies. Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeELOXX PHARMACEUTICALS ($ELOX) Releases Q3 2026 Earnings | ELOX Stock NewsELOXX Pharmaceuticals reported Q3 2026 earnings of -$0.49 per share, beating estimates of -$0.59, with revenue of $0. The stock fell 3.8% after market open. Analysts have issued buy ratings and a median price target of $39.0.MarketScreenerEloxx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Eloxx Pharmaceuticals reported a Q3 net loss of $5.54 million, up from $0.351 million a year ago, and a nine-month net loss of $13.8 million, up from $3.95 million. Basic and diluted loss per share from continuing operations were $0.49 and $1.83, respectively, compared to $0.58 and $9.12 a year ago.American Banking and Market NewsEloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Stock Has Average Price Target of $37.33 According to BrokeragesEloxx Pharmaceuticals has a consensus 'Moderate Buy' rating from seven analysts, with an average 12-month price target of $37.33. The stock opened at $13.01, and the company reported a quarterly loss of $0.66 per share, with analysts expecting a full-year loss of $2.61 per share.American Banking and Market NewsEloxx Pharmaceuticals (ELOXD) Expected to Announce Earnings on TuesdayEloxx Pharmaceuticals is expected to report earnings on Tuesday, November 10th, with analysts projecting a loss of $0.5767 per share. The stock opened at $6.20, with a 50-day moving average of $6.20 and a 200-day average of $3.88. The company focuses on therapies for genetic diseases caused by nonsense mutations.The future of tradingEloxx Pharmaceuticals to Present at 3rd Annual Guggenheim Healthcare Innovation ConferenceEloxx Pharmaceuticals will present at the 3rd Annual Guggenheim Healthcare Innovation Conference on November 9-11, 2026. President and CEO Sumit Aggarwal will speak from 11:30 to 11:55 a.m. ET on November 9.American Banking and Market NewsGuggenheim Issues Pessimistic Forecast for Eloxx Pharmaceuticals (NASDAQ:ELOX) Stock PriceGuggenheim lowered its Eloxx Pharmaceuticals target price to $40 from $43, keeping a buy rating. The stock opened at $13.20, with a consensus price target of $37.33 and a Moderate Buy rating. The company reported a loss of $0.66 per share for the quarter.Investing.comEloxx receives FDA clearance for ADPKD drug trial in U.S.Eloxx Pharmaceuticals received FDA clearance for its Investigational New Drug application for exaluren to treat nonsense-mutation autosomal dominant polycystic kidney disease. The clearance opens U.S. sites for the EXPRESS Phase 2 trial, which will enroll about 60 adults and dose the first patient in Q3 2027, with topline results expected in H1 2029.TradingViewGuggenheim maintains Buy rating on Eloxx Pharma, $40 price targetGuggenheim maintained a Buy rating on Eloxx Pharma with a $40 price target, implying a 199.9% upside from the Oct 27 close of $13.34. The analyst note highlights a finalized 52-week Phase 2 trial design for exaluren in ADPKD and the appointment of Dr. T.R. Srinivas as CMO.Investing.comGuggenheim cuts Eloxx Pharma stock price target on trial timelineGuggenheim lowered its Eloxx Pharma price target to $40 from $43, keeping a Buy rating. The cut follows the company's decision to extend its Phase 2 trial of exaluren in ADPKD to 52 weeks, pushing topline data to 2029. The firm expects a confirmatory pivotal trial and sales in 2033.The future of tradingEloxx Pharmaceuticals Appoints Geno J. Germano to BoardEloxx Pharmaceuticals appointed Geno J. Germano to its board on October 19, 2026, expanding the board from five to six directors. Germano's term expires at the 2027 annual shareholder meeting. He previously served as president and CEO of Elucida Oncology from August 2018 to June 2024.